DKSH Business Unit Healthcare has struck a new strategic partnership with Sanofi to expand access to key cardiovascular and diabetes treatments across Malaysia, Singapore, and Thailand.

 

The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease.

 

The collaboration will leverage DKSH’s end-to-end commercialization and market expansion services to improve patient access to established therapies, particularly in cardiovascular care across Malaysia, Singapore, and Thailand, and diabetes treatments in Singapore and Thailand.

 

Across ASEAN, rising life expectancy, shifting lifestyles, and growing demand for higher-quality care are driving a sharp increase in non-communicable diseases. 

 

Cardiovascular disease and diabetes remain among the most widespread and impactful health challenges in Southeast Asia, putting pressure on healthcare systems that must now balance regulatory complexity with urgent patient needs.

 

DKSH said its integrated “agency alliance” model will support Sanofi with full-scale commercial and medical capabilities, combining healthcare professional engagement, distribution infrastructure, and market execution to strengthen treatment access and continuity of care.

 

“This partnership with DKSH is a meaningful step in strengthening how we serve patients. With DKSH’s proven healthcare expertise and strong commercial capabilities in Southeast Asia, we can broaden access to established treatments, enhance the experience for healthcare professionals and patients, and stay agile as market needs evolve. 

 

"Above all, we are committed to working together to help strengthen the region’s healthcare ecosystem,” said Eric Mansion, General Manager Pharma Southeast Asia and India & MCO Lead, Sanofi.

 

DKSH emphasized its role in delivering healthcare access through its regional commercialization platform and deep expertise in chronic disease areas.

 

"We are thrilled to further expand our strategic partnership with Sanofi. We appreciate that Sanofi recognizes DKSH’s proven track record and differentiated capabilities of our commercialization platform, specifically related to customer insights, omni-channel engagement and enhancing patient access as well as adherence. 

 

"Through this collaboration, we aim to help improve access to treatment as part of our mission to deliver better healthcare for all. By combining our expertise as the leading healthcare commercialization business partner in the region with Sanofi’s Cardiovascular and Diabetes portfolio, we look forward to delivering meaningful impact for patients,” said Patrik Grande, Global Head of Business Unit Healthcare, DKSH.

 

The partnership signals a deeper push by both companies to strengthen regional healthcare ecosystems while improving access to essential chronic disease treatments across Southeast Asia.